Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836879 | 0.90 | SIGMAR1 (0.41) | TP53THRBALDH1A1SIGMAR1 | |
| SCHEMBL4840182 | 0.89 | SIGMAR1 (0.41) | TP53THRBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL4832377 | 0.87 | SIGMAR1 (0.43) | TP53THRBSIGMAR1 | |
| SCHEMBL4836692 | 0.85 | POLB (0.49) | THRBLMNASIGMAR1 | |
| SCHEMBL4837103 | 0.84 | SIGMAR1 (0.41) | TP53SIGMAR1 | |
| SCHEMBL4840596 | 0.83 | SIGMAR1 (0.46) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL4832361 | 0.81 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL4832522 | 0.81 | GPR119 (0.43) | THRBSIGMAR1 | |
| SCHEMBL4837332 | 0.81 | OPRD1 (0.47) | THRBLMNAALDH1A1SIGMAR1 | |
| SCHEMBL4838582 | 0.81 | SIGMAR1 (0.40) | THRBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | TP53 2550/4885THRB 1735/4885LMNA 904/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | TP53 4473/4885THRB 4088/4885LMNA 70/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | TP53 4473/4885THRB 4088/4885LMNA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.